Hangzhou Tigermed Consulting Co., Ltd.
HKSE: 3347.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Xiaoping Ye D.Phil
- Employees
- 10,185
- Headquarters
- Hangzhou, China
- IPO year
- 2020
- Market cap
- HK$46.3B
- Website
- https://www.tigermed.net
Loading 3347…
Loading profile data…Frequently asked questions about 3347
What does Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) do?
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice...
Where does 3347.HK trade?
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) trades on the Hong Kong Stock Exchange.
What sector is 3347.HK in?
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Hangzhou Tigermed Consulting Co., Ltd.?
Xiaoping Ye D.Phil is the chief executive officer of Hangzhou Tigermed Consulting Co., Ltd. (3347.HK).
Where is Hangzhou Tigermed Consulting Co., Ltd. headquartered?
Hangzhou Tigermed Consulting Co., Ltd. is headquartered in China.
Does 3347.HK pay a dividend?
Yes — Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) paid a trailing twelve-month dividend of HKD 0.32 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 3347.HK go public?
Hangzhou Tigermed Consulting Co., Ltd. (3347.HK) completed its initial public offering in 2020.